Products
PRIMARY ANTIBODY
SECONDARY ANTIBODY
PROTEIN & PEPTIDES
BIOCHEMICALS
ASSAY & ELISA KITS
LOADING CONTROL
OTHER REAGENTS
SERUMS
CELL LINE
Contact Us
About Us
Login
Register
|
Forgot Password
Sign In
Forgot your Password?
If you've forgotten your password, enter your e-mail address below and we'll send you instructions on how to securely change your password.
Back
Continue
0
Shopping Cart
Products
Contact Us
About Us
Shopping Cart
Loading....
Login Account
Sign In
Register
Register
|
Forgot Password
Sign In
Forgot your Password?
If you've forgotten your password, enter your e-mail address below and we'll send you instructions on how to securely change your password.
Back
Continue
0
Shopping Cart
Home
BioChemicals
Trilaciclib
tcsc0021431
Trilaciclib
Order Now
AVAILABLE SIZES
5mg
10mg
50mg
100mg
$
1,000.00
Add to Cart
ORDERING INFORMATION
International
TAICLONE BIOTECH CORP.
order@taiclone.com
+886-2-2735-9682
+886-2-2735-9807
Data sheet
Download PDF Datasheet
Technical Inquries
Submit Review
Submit Review
Please choose your application, enter the information requested below. * Marked fields are mandatory.
Full Name
Email
Contact Number
Application
Please Select..
Western blot (WB)
Immunohistochemistry (IHC)
Immunofluorescence (IF)
Immunocytochemistry (ICC)
Immunoprecipitation (IP)
Co-Immunoprecipitation (CoIP)
Chromatin Immunoprecipitation (ChIP)
RNA Binding Protein Immunoprecipitation (RIP)
Sample
Loading Amount
Loading Type
UG
CELLS
Treatment
Temperature
Exposure
Observe Band
Fixative
Select One
Acetone
Formaldehyde
Methanol
Paraformaldehyde
Other
Antigen Retrieval
Select One
Heat mediated
Enzymatic
Other
None
Positive Control
Negative Control
Dilution *
1:
Incubation Time *
Select Image *
Choose a file...
Rating *
Remarks *
Submit Review
Product Description
Trilaciclib is a
CDK4/6
inhibitor with
IC
50
s of 1 nM and 4 nM for CDK4 and CDK6, respectively.
IC50 & Target: IC50: 1 nM (CDK4), 4 nM (CDK6)
[1]
In Vitro:
Incubation with Trilaciclib (G1T28) for 24 hours induces a robust G
1
cell-cycle arrest (time=0). By 16 hours after Trilaciclib hydrochloride washout, cells have reentered the cell cycle and demonstrate cell-cycle kinetics similar to untreated control cells. These results demonstrate that Trilaciclib causes a transient, and reversible G
1
arrest. A transient Trilaciclib-mediated G
1
cell-cycle arrest in CDK4/6-sensitive cells decreases the
in vitro
toxicity of a variety of commonly used cytotoxic chemotherapy agents associated with myelosuppression
[1]
.
In Vivo:
Trilaciclib (G1T28) treatment results in a robust and dose-dependent suppression of proliferation in HSPCs at 12 hours, with EdU incorporation returning near baseline levels in a dose-dependent manner by 24 hours after administration. These data demonstrate that a single oral dose of Trilaciclib can produce reversible cell-cycle arrest in HSPCs in a dose-dependent manner
in vivo
. Mice given 100 mg/kg Trilaciclib 30 minutes prior to etoposide treatment, exhibits only background levels of caspase-3/7 activity. These data demonstrate that Trilaciclib can protect the bone marrow from chemotherapy-induced apoptosis
in vivo
. The data demonstrate that treatment with Trilaciclib prior to 5-FU likely decreases 5-FU-induced damage by chemotherapy in HSPCs, thus accelerating blood count recovery after chemotherapy
[1]
.
Information
CAS No
1374743-00-6
Formula
C
24
H
30
N
8
O
Clinical Information
clinicalinformation
Pathway
Cell Cycle/DNA Damage
Target
CDK
Specifications
Purity / Grade
>98%
Solubility
10 mM in DMSO
Smiles
smiles
Misc Information
Alternative Names
G1T28
Observed Molecular Weight
446.55
related data
Get valuable resources and offers directly to your email.
REGISTER NOW